About: Development of treatment and clinical results in childhood AML in Austria (1993

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of treatment and clinical results in childhood AML in Austria (1993–2013) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development of treatment and clinical results in childhood AML in Austria (1993–2013)
Creator	Gadner, Helmut Lion, Thomas Jones, N Attarbaschi, Andishe Boztug, Heidrun Boztug, H Dworzak, Michael Fink, F.-M Fink, Franz-Martin Glogova, Evgenia Haas, Oskar Jones, Neil Mann, Georg Meister, B Meister, Bernhard Mühlegger, Nora Pötschger, Ulrike Schmitt, K Schmitt, Klaus Strehl, Sabine Urban, Christian Urban, C
Source	PMC
abstract	BACKGROUND: Since the early 1990s, three consecutive pediatric acute myeloid leukemia (AML) trials have been performed in Austria (AML-Berlin-Frankfurt-Münster (BFM) 93, AML-BFM 98, and AML-BFM 2004) in close cooperation with the international BFM study center. Herein, we review the pertinent patient characteristics, therapy, and outcome data. PATIENTS AND METHODS: From January 1993 to April 2013, 249 children and adolescents (193 protocol patients) diagnosed with AML were enrolled in the three BFM studies. Patients were mainly treated in one of five pediatric hematology/oncology centers distributed over Austria. RESULTS: Many characteristics and outcome parameters were not statistically different between the three trials. Almost similar proportions of patients were stratified into two risk groups: standard risk (SR) (approximately 37 % overall) and high-risk (HR) (61 %). MLL rearrangements were found in 23 % of patients overall as the most frequent genetic aberration subtype. Complete remission (CR) was achieved by 84–95 % of patients. The most important type of event was leukemic relapse (5-year cumulative incidence 40 ± 8 %, 21 ± 5 %, and 39 ± 6 %; p = 0.058), with a trend to a higher rate specifically in SR patients of study AML-BFM 2004 compared with AML-BFM 98. Importantly, the frequency of death from causes other than relapse sequelae declined over the years (AML-BFM 93: 5/42 12 %, AML-BFM 98: 5/57 9 %, and AML-BFM 2004: 5/94 5 %). Altogether, event-free survival at 5 years varied insignificantly (48 ± 8 %, 61 ± 7 %, and 50 ± 6 %; p = 0.406). Nevertheless, survival (pSU) apparently improved from BFM 93 to subsequent studies, both overall (57 ± 8 %, 75 ± 6 %, and 62 ± 6 %; p = 0.046) and regarding the HR group (5-year-probability of survival (pSU) 40 ± 10 %, 66 ± 8 %, and 52 ± 8 %; p = 0.039). CONCLUSION: Treatment of pediatric AML in Austria renders survival rates in the range of international best practice. However, unambiguous statistical comparison of treatment periods is eventually hampered by small numbers and inequalities of recruitment. Hence, only internationally collaborative trials will allow developing treatment further to achieve higher cure rates with fewer events.
has issue date	2014-03-01(xsd:dateTime)
bibo:doi	10.1007/s12254-014-0135-y
bibo:pmid	32288851
has license	no-cc
sha1sum (hex)	f20db6641171fe3363087e166dd1241dd30407d6
schema:url	https://doi.org/10.1007/s12254-014-0135-y
resource representing a document's title	Development of treatment and clinical results in childhood AML in Austria (1993–2013)
has PubMed Central identifier	PMC7102234
has PubMed identifier	32288851
schema:publication	Memo
resource representing a document's body	covid:f20db6641171fe3363087e166dd1241dd30407d6#body_text
is schema:about of	covid:arg/f20db6641171fe3363087e166dd1241dd30407d6 named entity 'acute myeloid leukemia' named entity 'AML' named entity 'Austria' named entity 'conventional therapy' named entity 'idarubicin' named entity 'chemotherapy' named entity 'AML' named entity 'AML' named entity 'pediatric' named entity 'Austria' named entity 'morbidity' named entity 'MLL' named entity 'serum glutamic oxaloacetic transaminase' named entity 'Austria' named entity 'multidrug resistance' named entity 'prognosis' named entity 'pediatric' named entity 'pediatric' named entity 'M3 subtype' named entity 'relapse' named entity 'AML' named entity 'relapse' named entity 'cephalosporins' named entity 'neutropenia' named entity 'Idarubicin' named entity 'Etoposide' named entity 'clinical trials' named entity 'Ara-C' named entity 'work-up' named entity 'comorbidities' named entity 'AML' named entity 'leukemias' named entity 'chemotherapy' named entity 'supportive therapy' named entity 'AML' named entity 'acute myeloid leukemia' named entity 'ADE' named entity 'VGS' named entity 'leukemic' named entity 'aplasia' named entity 'toxicity' named entity 'AF9' named entity 'informed consent' named entity 'Autologous' named entity 'irradiation' named entity 'gene' named entity 'treatment regimens' named entity 'Daunorubicin' named entity 'ARDS' named entity 'relapse' named entity 'pediatric' named entity 'ATRA' named entity 'pEFS' named entity 'Etoposide' named entity 'refractory' named entity 'heterogeneous disease' named entity 'relapse' named entity 'allogeneic' named entity 'prophylaxis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software